| 05/16 | Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di.. | GL |
| 05/16 | Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di.. | AQ |
| 05/16 | Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Di.. | CI |
| 05/13 | KeyBanc Lowers Exagen's Price Target to $17 From $20, Maintains Overweight Rating | MT |
| 05/11 | EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results
.. | AQ |
| 05/11 | Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 05/11 | TRANSCRIPT : Exagen Inc., Q1 2022 Earnings Call, May 11, 2022 | CI |
| 05/11 | Earnings Flash (XGN) EXAGEN Reports Q1 Revenue $10.4M, vs. Street Est of $10M | MT |
| 05/11 | Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te.. | GL |
| 05/11 | Exagen Inc. Reports First Quarter 2022 Results | GL |
| 05/11 | Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te.. | AQ |
| 05/11 | Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Te.. | CI |
| 05/11 | Exagen Inc. Reports First Quarter 2022 Results | AQ |
| 05/11 | Exagen Inc. Revises Revenue Guidance for the Full Year of 2022 | CI |
| 05/01 | Exagen Announces Five-Week Campaign for Lupus Awareness Month | AQ |
| 05/01 | Exagen Announces Five-Week Campaign for Lupus Awareness Month | GL |
| 04/28 | EXAGEN INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits.. | AQ |
| 04/25 | Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022 | AQ |
| 04/20 | Exagen Inc. to Participate in Investor Summit Group's Q2 Conference | GL |
| 03/30 | Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems | AQ |
| 03/30 | Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems | CI |
| 03/25 | KeyBanc Adjusts Exagen's Price Target to $20 From $30, Reiterates Overweight Rating | MT |
| 03/23 | Cowen Adjusts Exagen's Price Target to $16 from $26, Reiterates Outperform Rating | MT |
| 03/22 | EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results
.. | AQ |
| 03/22 | TRANSCRIPT : Exagen Inc., Q4 2021 Earnings Call, Mar 22, 2022 | CI |
| 03/22 | Exagen Q4 Loss Widens, Revenue Flat; Full-Year Sales Guidance Trails Street View | MT |
| 03/22 | EXAGEN : Reports Fourth Quarter and Full Year 2021 Results - Form 8-K | PU |
| 03/22 | Earnings Flash (XGN) EXAGEN Reports Q4 Revenue $12.7M, vs. Street Est of $11.7M | MT |
| 03/22 | Earnings Flash (XGN) EXAGEN Posts Q4 Loss $-0.42, vs. Street Est of $-0.46 | MT |
| 03/22 | Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives | AQ |
| 03/22 | Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results | GL |
| 03/22 | Exagen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2021 | CI |
| 03/22 | Exagen Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 | CI |
| 03/22 | Exagen Inc. Provides Revenue Guidance for the Full Year 2022 | CI |
| 03/16 | Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board | GL |
| 03/16 | Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board | GL |
| 03/16 | Exagen Inc. Announces Board Appointments | CI |
| 03/09 | Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTec.. | GL |
| 03/08 | Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022 | GL |
| 02/02 | Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Dia.. | AQ |
| 01/10 | EXAGEN INC. : Regulation FD Disclosure (form 8-K) | AQ |
| 01/10 | Exagen, Queen Mary University to Collaborate on Molecular Signatures for Rheumatoid Art.. | MT |
| 01/09 | Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collabor.. | AQ |
| 01/09 | Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collabor.. | CI |
| 2021 | Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conferen.. | GL |
| 2021 | Exagen Inc. to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conferen.. | GL |
| 2021 | KeyBanc Adjusts Price Target on Exagen to $30 from $33, Keeps Overweight Rating | MT |
| 2021 | EXAGEN INC. Management's Discussion and Analysis of Financial Condition and Results
.. | AQ |
| 2021 | TRANSCRIPT : Exagen Inc., Q3 2021 Earnings Call, Nov 10, 2021 | CI |
| 2021 | Exagen Inc. Reports Third Quarter 2021 Results - Form 8-K | PU |
| 2021 | Earnings Flash (XGN) EXAGEN Reports Q3 Revenue $12.3M, vs. Street Est of $12.1M | MT |
| 2021 | Earnings Flash (XGN) EXAGEN Posts Q3 Loss $-0.42, vs. Street Est of $-0.47 | MT |
| 2021 | EXAGEN INC. : Results of Operations and Financial Condition (form 8-K) | AQ |
| 2021 | Exagen Inc. Reports Third Quarter 2021 Results | AQ |
| 2021 | Exagen Inc. Provides Revenue Guidance the Full Year 2021 | CI |
| 2021 | Exagen Inc. to Participate in the 2021 Canaccord Genuity Virtual MedTech, Diagnostics a.. | AQ |
| 2021 | Exagen to Announce Third Quarter 2021 Financial Results on November 10, 2021 | GL |
| 2021 | Exagen Inc. Expands Coverage with Inland Empire Health Plan, Partnering to Provide More.. | AQ |
| 2021 | Exagen Inc. Partners with Inland Empire Health Plan | CI |
| 2021 | EXAGEN : Refinances $27.2 Million of Debt | MT |
| 2021 | EXAGEN : Announces $27.2 Million Debt Refinancing - Form 8-K | PU |
| 2021 | EXAGEN INC. : Entry into a Material Definitive Agreement (form 8-K) | AQ |
| 2021 | EXAGEN INC : . Announces $27.2 Million Debt Refinancing | AQ |
| 2021 | Exagen Inc. Announces $27.2 Million Debt Refinancing | CI |
| 2021 | EXAGEN : Showcases Eight Scientific Presentations at ACR's Virtual Annual Meeting in Novem.. | AQ |
| 2021 | EXAGEN INC. : Entry into a Material Definitive Agreement (form 8-K) | AQ |
| 2021 | EXAGEN INC.(NASDAQGM : XGN) added to S&P Global BMI Index | CI |
| 2021 | EXAGEN INC : . to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conf.. | AQ |
| 2021 | EXAGEN INC. : Entry into a Material Definitive Agreement (form 8-K) | AQ |
| 2021 | EXAGEN : Posts Wider Q2 Loss, Higher Revenue; Company Maintains Full-Year Revenue Outlook | MT |
| 2021 | EXAGEN : BTIG Adjusts Exagen's Price Target to $20 From $23, Reiterates Buy Rating | MT |
| 2021 | EXAGEN : Management's Discussion and Analysis of Financial Condition and Results of Operat.. | AQ |
| 2021 | EXAGEN : Earnings Flash (XGN) EXAGEN Reports Q2 Loss $-0.38, vs. Street Est of $-0.44 | MT |
| 2021 | EXAGEN : Earnings Flash (XGN) EXAGEN Posts Q2 Revenue $12.8M, vs. Street Est of $11.4M | MT |
| 2021 | TRANSCRIPT : Exagen Inc., Q2 2021 Earnings Call, Aug 09, 2021 | CI |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
